The DOI matches its Crossref record; 582 of the 582 references it cites were found in a registry or an index.
Inhibition and induction of human cytochrome P450 enzymes: current status
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–582 of 582
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism
Benowitz, N. L., Peng, M., & Jacob, P. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.07.001 · Cited by 96
A QSAR Evaluation of Ah Receptor Binding of Halogenated Aromatic Xenobiotics
Mekenyan, O. G., Veith, G. D., Call, D. J., & Ankley, G. T. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.961041302 · Cited by 96
Gebhardt, A. C., Lucas, D., Menez, J. F., & Seitz, H. K. (1997) · Hepatology · doi:10.1002/hep.510260423 · Cited by 96
Increase in tacrolimus trough levels after steroid withdrawal
van Duijnhoven, E. M., Boots, J. M. M., Christiaans, M. H. L., Stolk, L. M., Undre, N. A., & van Hooff, J. P. (2003) · Transplant International · doi:10.1007/s00147-003-0615-1 · Cited by 95
Jiang, X., Blair, E. Y. L., & McLachlan, A. J. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006292124 · Cited by 95
Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells
Hukkanen, J., Väisänen, T., Lassila, A., Piipari, R., Anttila, S. L., Pelkonen, O., Raunio, H., & Hakkola, J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038208 · Cited by 95
Self-citationInfluence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Glaeser, H., Drescher, S., Eichelbaum, M. F., & Fromm, M. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02265.x · Cited by 94
Mildvan, D., Yarrish, R. L., Marshak, A., Hutman, H. W., McDonough, M., Lamson, M. J., & Robinson, P. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200204150-00007 · Cited by 94
Artemisinin induces omeprazole metabolism in human beings*
Svensson, U. S. H., Ashton, M., Hai, T. N., Bertilsson, L., Huong, D. X., Hướng, N. V., Niêu, N. T., Sy, N. D., Lykkesfeldt, J., & Công, L. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90149-7 · Cited by 94
Martin, H., Sarsat, J. P., de Waziers, I., Housset, C., Balladur, P., Beaune, P. H., Albaladejo, V., & Lerche-Langrand, C. (2003) · Pharmaceutical Research · doi:10.1023/a:1023234429596 · Cited by 93
Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
Edwards, R. J., Price, R. J., Watts, P. S., Renwick, A. B., Tredger, J. M., Boobis, A. R., & Lake, B. G. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.282 · Cited by 92
Effect of rifampicin on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02515.x · Cited by 89
ELETRIPTAN METABOLISM BY HUMAN HEPATIC CYP450 ENZYMES AND TRANSPORT BY HUMAN P-GLYCOPROTEIN
Evans, D. C., O'Connor, D. V., Lake, B. G., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.861 · Cited by 89
Perucca, E., Grimaldi, R., Frigo, G. M., Sardi, A., M�nig, H., & Ohnhaus, E. E. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00615223 · Cited by 89
Nielsen, T. L., Rasmussen, B. B., Flinois, J.-P., Beaune, P. H., & Brøsen, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38103-0 · Cited by 89
Tang, C., Lin, J. H., & Lu, A. Y. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003236 · Cited by 89
Ekström, G., & Gunnarsson, U. B. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07489-6 · Cited by 89
Cell-based models to study hepatic drug metabolism and enzyme induction in humans
Vermeir, M., Annaert, P., Mamidi, R. N. V. S., Roymans, D., Meuldermans, W., & Mannens, G. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.75 · Cited by 88
Chimeric mice with humanized liver
Katoh, M., Tateno, C., Yoshizato, K., & Yokoi, T. (2007) · Toxicology · doi:10.1016/j.tox.2007.11.012 · Cited by 88
Palovaara, S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00202-9 · Cited by 87
Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y., & Yokoi, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006254 · Cited by 86
The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling
Schuster, D., & Langer, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049722q · Cited by 86
Rencurel, F., Foretz, M., Kaufmann, M., Stroka, D., Looser, R., Leclerc, I., Xavier, G. D. S., Rutter, G. A., Viollet, B., & Meyer, U. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.029421 · Cited by 86
He, N., & Edeki, T. I. (2004) · American Journal of Therapeutics · doi:10.1097/00045391-200405000-00009 · Cited by 85
Weber, C., Banken, L., Birnboeck, H., & Schulz, R. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008380 · Cited by 85
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
Bidstrup, T. B., Stilling, N. M., Damkier, P., Scharling, B., Thomsen, M. S., & Brøsen, K. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0746-z · Cited by 84
DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL
Wang, Y.-H., Jones, D. R., & Hall, S. D. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001834 · Cited by 84
Modulation of Mouse and Human Phenobarbital-Responsive Enhancer Module by Nuclear Receptors
Mäkinen, J., Frank, C., Jyrkkärinne, J., Gynther, J., Carlberg, C., & Honkakoski, P. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.366 · Cited by 84
Self-citationInhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes
Yeo, K. R., & Yeo, W. W. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01386.x · Cited by 83
Hakkola, J., Raunio, H., Purkunen, R., Saarikoski, S., Vähäkangas, K., Pelkonen, O., Edwards, R. J., Boobis, A. R., & Pasanen, M. (2001) · Neonatology · doi:10.1159/000047142 · Cited by 82
Self-citationBiotransformation of alprazolam by members of the human cytochrome P4503A subfamily
Gorski, J. C., Jones, D. R., Hamman, M. A., Wrighton, S. A., & Hall, S. D. (1999) · Xenobiotica · doi:10.1080/004982599238173 · Cited by 82
Birkett, D., Rees, D. L. P., Andersson, T., Gonzalez, F. J., Miners, J. O., & Veronese, M. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05707.x · Cited by 81
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects
Asimus, S., Elsherbiny, D. A., Hai, T. N., Jansson, B., Hướng, N. V., Petzold, M., Simonsson, U. S. H., & Ashton, M. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00471.x · Cited by 81
The Influence of St. John's Wort on CYP2C19 Activity with Respect to Genotype
Wang, L., Zhu, B. Y., El‐Aty, A. M. A., Zhou, G., Li, Z., Wu, J., Chen, G., Liu, J., Tang, Z., An, W., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265642 · Cited by 81
Waller, C. L., & McKinney, J. D. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00098a010 · Cited by 80
The H4IIE Cell Bioassay as an Indicator of Dioxin-like Chemicals in Wildlife and the Environment
White, J. J., Schmitt, C. J., & Tillitt, D. E. (2004) · Critical Reviews in Toxicology · doi:10.1080/10408440490265193 · Cited by 80
Gómez-Lechón, M. J., Donato, M. T., Jover, R., Rodríguez‐Antona, C., Ponsoda, X., Glaise, D., Castell, J. V., & Guguen‐Guillouzo, C. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02011.x · Cited by 79
Real-Time Polymerase Chain Reaction Analysis of CYP1B1 Gene Expression in Human Liver
Chang, T. K. H., Chen, J., Pillay, V., Ho, J.-Y., & Bandiera, S. M. (2003) · Toxicological Sciences · doi:10.1093/toxsci/71.1.11 · Cited by 79
Koike, C., Moore, R., & Negishi, M. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034538 · Cited by 79
Huuskonen, P., Storvik, M., Reinisalo, M., Honkakoski, P., Rysä, J., Hakkola, J., & Pasanen, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100376 · Cited by 79
Self-citationKobayashi, K., Yamamoto, T., Chiba, K., Tani, M., Ishizaki, T., & Kuroiwa, Y. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05793.x · Cited by 78
Human liver microsomal metabolism of paclitaxel and drug interactions
Desai, P. B., Duan, J. Z., Zhu, Y., & Kouzi, S. A. (1998) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03192303 · Cited by 78
In silico tools to aid risk assessment of endocrine disrupting chemicals
Jacobs, M. N. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.036 · Cited by 78
Involvement of Human CYP1A Isoenzymes in the Metabolism and Drug Interactions of Riluzole In Vitro
Sanderink, G.-J., Bournique, B., Stevens, J. C., Petry, M., & Martinet, M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36944-7 · Cited by 78
EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES
Roymans, D., Annaert, P., Houdt, J. V., Weygers, A., Noukens, J., Sensenhauser, C., Silva, J., Looveren, C. V., Hendrickx, J., Mannens, G., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003046 · Cited by 78
Funck‐Brentano, C., Becquemont, L., Leneveu, A., Roux, A., Jaillon, P., & Beaune, P. H. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36460-2 · Cited by 77
Arulmozhiraja, S., & Morita, M. (2004) · Chemical Research in Toxicology · doi:10.1021/tx0300380 · Cited by 77
In Silico Prediction of Pregnane X Receptor Activators by Machine Learning Approache
Ung, C. Y., Li, H., Yap, C. W., & Chen, Y. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027623 · Cited by 77
Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver.
Hu, Y., Мишин, В. М., Johansson, I., von Bahr, C., Cross, A. J., Ronis, M. J. J., Badger, T. M., & Ingelman‐Sundberg, M. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38876-2 · Cited by 77
Boobis, A. R., Murray, S., Kahn, G. C., Robertz-Vaupel, G.-M., & Davies, D. S. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14267-3 · Cited by 76
Lucas, D., Ménez, C., Girre, C., Bodénez, P., Hispard, É., & Menez, J. F. (1995) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1995.tb01516.x · Cited by 74
Sotaniemi, E. A., Rautio, A., Backstrom, M., Arvela, P. I., & Pelkonen, O. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04412.x · Cited by 74
Self-citationRoberts, E. A., Johnson‐Henry, K. C., Harper, P. A., & Okey, A. B. (1990) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(90)90743-i · Cited by 74
Characterization of the inhibition of P4501A2 by furafylline
Clarke, S. E., Ayrton, A. D., & Chenery, R. J. (1994) · Xenobiotica · doi:10.3109/00498259409043254 · Cited by 74
The Challenge of Predicting Drug Toxicityin silico
Vedani, A., Dobler, M., & Lill, M. A. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_471.x · Cited by 74
Ogg, M. S. (1999) · Xenobiotica · doi:10.1080/004982599238669 · Cited by 74
Broly, F., Libersa, C., Lhermitte, M., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03502.x · Cited by 74
Hewitt, N. J., de Kanter, R., & LeCluyse, E. L. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.009 · Cited by 72
Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole
Saußele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A. K., Nüssler, N. C., Hengstler, J. G., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100138 · Cited by 72
Gt, T. (1992) · PubMed · Cited by 72
Kent, U. M., Mills, D. E., Rajnarayanan, R. V., Alworth, W. L., & Hollenberg, P. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.549 · Cited by 71
Cytochrome P450 in Human Fetal Liver: Significance and Fetal-Specific Expresson
Kitada, M., & Kamataki, T. (1994) · Drug Metabolism Reviews · doi:10.3109/03602539409029800 · Cited by 71
Roy, P., Tretyakov, O., Wright, J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14934-3 · Cited by 71
Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs
van Leeuwen, D. M., van Agen, E., Gottschalk, R. W. H., VLIETINCK, R. F., Gielen, M., van Herwijnen, M. H. M., Maas, L. M., Kleinjans, J. C. S., & van Delft, J. H. M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl199 · Cited by 71
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test
Parker, A. C., Pritchard, P., Preston, T., & Choonara, I. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00684.x · Cited by 70
METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES
Klees, T. M., Sheffels, P. R., Dale, O., & Kharasch, E. D. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002709 · Cited by 70
Correlation of High-Throughput Pregnane X Receptor (PXR) Transactivation and Binding Assays
Zhu, Z., Kim, S. T., Chen, T., Lin, J.-H., Bell, A., Bryson, J., Dubaquié, Y., Yan, N., Yanchunas, J., Xie, D., et al. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104264902 · Cited by 70
Sahi, J., Milad, M. A., Zheng, X., Rose, K., Wang, H., Stilgenbauer, L., Gilbert, D., Jolley, S. L., Stern, R. H., & LeCluyse, E. L. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050526 · Cited by 70
Rodríguez‐Antona, C., Niemi, M., Backman, J. T., Kajosaari, L. I., Neuvonen, P. J., Robledo, M., & Ingelman‐Sundberg, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500482 · Cited by 70
Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation
Tracy, T. S., Marra, C., Wrighton, S. A., et al. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050293 · Cited by 67
Kobayashi, K., Yamanaka, Y., Iwazaki, N., Nakajo, I., Hosokawa, M., Negishi, M., & Chiba, K. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002741 · Cited by 67
Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes
Yueh, M., Kawahara, M. S., & Raucy, J. L. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.10.003 · Cited by 66
Kanebratt, K. P., Ekehed, S., Otter, C. A., Lutz, M., McPheat, J., Masimirembwa, C. M., & Andersson, T. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8812-5 · Cited by 66
Comparison of Basal Gene Expression and Induction of CYP3As in HepG2 and Human Fetal Liver Cells
Maruyama, M., Matsunaga, T., Harada, E., & Ohmori, S. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.2091 · Cited by 66
STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES
Kim, K., Kim, M. J., Park, J. Y., Shon, J., Yoon, Y.-R., Lee, S.-S., Liu, K., Chun, J., Hyun, M. H., & Shin, J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1227 · Cited by 66
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
Depré, M., Hecken, A. V., Oeyen, M., Lepeleire, I. D., Laethem, T., Rothenberg, P., Petty, K. J., Majumdar, A. K., Crumley, T. M., Panebianco, D. L., et al. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0907-8 · Cited by 65
van Giersbergen, P. L. M., Treiber, A., Clozel, M., Bodin, F., & Dingemanse, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122473 · Cited by 65
Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.
Fuhr, U., Wolff, T., Harder, S., Schymanski, P., & Staib, A. H. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08659-3 · Cited by 65
Inhibitory effects of antiarrhythmic drugs on phenacetin O‐deethylation catalysed by human CYP1A2
Kobayashi, K., Nakajima, M., Chiba, K., et al. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00692.x · Cited by 64
Amiodarone N‐Deethylation by CYP2C8 and its Variants, CYP2C8*3 and CYP2C8 P404A
Soyama, A., Hanioka, N., Saito, Y., Murayama, N., Ando, M., Ozawa, S., & Sawada, J. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.910404.x · Cited by 64
Kahn, G. C., Boobis, A. R., Murray, S., Brodie, M. J., & Davies, D. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01430.x · Cited by 64
Functional analysis of the human cytochrome P4501A1 (CYP1A1) gene enhancer
Kress, S., Reichert, J., & Schwarz, M. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2580803.x · Cited by 64
Yamazaki, H., & Shimada, T. (1998) · PubMed · Cited by 64
Rasheed, A., Hines, R. N., & McCarver-May, D. G. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8152 · Cited by 63
Backman, J. T., Granfors, M. T., & Neuvonen, P. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0127-x · Cited by 63
Pinto, A. G., Wang, Y.-H., Chalasani, N., Skaar, T. C., Kolwankar, D., Gorski, J. C., Liangpunsakul, S., Hamman, M. A., Arefayene, M., & Hall, S. D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.002 · Cited by 63
Theophylline N-demethylations as probes for P4501A1 and P4501A2.
Sarkar, M. A., & Jackson, B. J. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08424-7 · Cited by 63
TRANS-3′-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES
Yamanaka, H., Nakajima, M., Katoh, M., Kanoh, A., Tamura, O., Ishibashi, H., & Yokoi, T. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001701 · Cited by 62
Tugnait, M., Hawes, E. M., McKay, G., Eichelbaum, M. F., & Midha, K. K. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00006-x · Cited by 61
Hruska, M. W., Amico, J. A., Langaee, T. Y., Ferrell, R. E., Fitzgerald, S. M., & Frye, R. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02263.x · Cited by 61
Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor
Jyrkkärinne, J., Windshügel, B., Mäkinen, J., Ylisirniö, M., Peräkylä, M., Poso, A., Sippl, W., & Honkakoski, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411241200 · Cited by 61
Self-citationSmith, G. B. J., Bend, J. R., Bedard, L. L., Reid, K. R., Petsikas, D., & Massey, T. E. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1134 · Cited by 61
Sumida, A., Fukuen, S., Yamamoto, I., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2029 · Cited by 60
Nishimura, M., YOSHITSUGU, H., Yokoi, T., Tateno, C., Kataoka, M., Horie, T., Yoshizato, K., & NAITO, S. (2005) · Xenobiotica · doi:10.1080/00498250500307251 · Cited by 60
Yasumori, T., Li, Q., Yamazoe, Y., Tsuzuki, T., Kato, R., & Ueda, M. (1994) · Pharmacogenetics · doi:10.1097/00008571-199412000-00005 · Cited by 59
Induction and drug development
Smith, D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00107-x · Cited by 59
Backman, J. T., Karjalainen, M. J., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02653.x · Cited by 59
Accumulation of caffeine in healthy volunteers treated with furafylline.
Tarrus, E., Camı́, J., Roberts, D., Spickett, R. G. W., Celdrán, E., & Segura, J. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03003.x · Cited by 59
Clarke, S. E., Baldwin, S. J., Bloomer, J. C., Ayrton, A. D., Sozio, R. S., & Chenery, R. J. (1994) · Chemical Research in Toxicology · doi:10.1021/tx00042a018 · Cited by 59
Lemaire, G., Benod, C. C., Nahoum, V., Pillon, A., Boussioux, A., Guichou, J., Subra, G., Pascussi, J., Bourguet, W., Chavanieu, A., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033415 · Cited by 59
Wójcikowski, J., Maurel, P., & Daniel, W. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006445 · Cited by 58
Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan
Wild, M. J., McKillop, D., & Butters, C. (1999) · Xenobiotica · doi:10.1080/004982599238290 · Cited by 58
Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung
Wei, C., Caccavale, R. J., Weyand, E. H., Chen, S., & Iba, M. M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00809-6 · Cited by 58
Regulation of the Cyp2a5 Gene Involves an Aryl Hydrocarbon Receptor-Dependent Pathway
Arpiainen, S., Raffalli‐Mathieu, F., Lang, M. A., Pelkonen, O., & Hakkola, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008078 · Cited by 57
Self-citationEffect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers
Robertson, P., Hellriegel, E., Arora, S., & Nelson, M. T. (2002) · Clinical pharmacology and therapy · doi:10.1067/mcp.2002.121217 · Cited by 57
Potent Inhibition of Cytochrome P-450 2D6-Mediated DextromethorphanO-Demethylation by Terbinafine
Abdel‐Rahman, S. M., Marcucci, K. A., Boge, T. C., Gotschall, R. R., KEARNS, G., & Leeder, J. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15224-5 · Cited by 55
Extent of Urinary Excretion of p-Hydroxyphenytoin in Healthy Subjects Given Phenytoin
DICKINSON, R. G., Hooper, W. D., Patterson, M. C., et al. (1985) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198507030-00008 · Cited by 55
Vignati, L., Bogni, A., Grossi, P., & Monshouwer, M. (2004) · Toxicology · doi:10.1016/j.tox.2003.12.018 · Cited by 55
Liu, F., Song, X., Yang, D., Deng, R., & Yan, B. (2007) · Biochemical Journal · doi:10.1042/bj20070613 · Cited by 53
Chou, C.-Y., Evans, A. M., Fornasini, G., & Rowland, M. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08184-x · Cited by 52
Metabolic interactions of methoxsalen and coumarin in humans and mice
Mäenpää, J., Juvonen, R. O., Raunio, H., Rautio, A., & Pelkonen, O. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90558-4 · Cited by 52
Self-citationA simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line
Trubetskoy, O. V., Marks, B. D., Zielinski, T. K., Yueh, M., & Raucy, J. L. (2005) · The AAPS Journal · doi:10.1208/aapsj070102 · Cited by 52
Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism
Wietholtz, H., Zysset, T., Kreiten, K., Kohl, D., B�chsel, R., & Matern, S. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558303 · Cited by 50
Expression and induction of CYP3As in human fetal hepatocytes
Matsunaga, T., Maruyama, M., Harada, E., Katsuyama, Y., Sugihara, N., Ise, H., Negishi, N., Ikeda, U., & Ohmori, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.041 · Cited by 49
Ethanol Increases Content and Activity of Human Cytochrome P4502E1 in a Transduced HepG2 Cell Line
Carroccio, A., Wu, D., & Cederbaum, A. I. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2242 · Cited by 49
Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401
Stevens, J. C., White, R. B., Hsu, S. H., & Martinet, M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36941-1 · Cited by 48
Smith, G. C., Ibbotson, S. H., Comrie, M., Dawe, R. S., Bryden, A., Ferguson, J., & Wolf, C. R. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07317.x · Cited by 48
Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4
Lau, W. C., & Gurbel, P. A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9084-4 · Cited by 48
In vitro metabolic interaction studies: Experience of the Food and Drug Administration
Yuan, R., PARMELEE, T., Balian, J. D., Uppoor, R. S., Ajayi, F., Burnett, A. L. “., Lesko, L. L., & Marroum, P. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70048-2 · Cited by 48
Furster, C., & Wikvall, K. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s0005-2760(98)00175-1 · Cited by 47
Frovatriptan: A Review of Drug‐Drug Interactions
Buchan, P., Wade, A., Ward, C., Oliver, S. D., Mfpm, Stewart, A. J., & Freestone, S. H. (2002) · Headache The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.42.s2.4.x · Cited by 47
CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay
Busi, F., & Cresteil, T. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014225 · Cited by 47
Comparison of (S)‐mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms
Coller, Somogyi, & Bochner (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00005.x · Cited by 46
Dailly, É., Tribut, O., Tattevin, P., Arvieux, C., Perré, P., Raffi, F., & Jolliet, P. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0122-2 · Cited by 45
Dual action of oestrogens on the mouse constitutive androstane receptor
MÄKINEN, J., REINISALO, M., NIEMI, K., VIITALA, P., JYRKKÄRINNE, J., CHUNG, H., PELKONEN, O., & HONKAKOSKI, P. (2003) · Biochemical Journal · doi:10.1042/bj20030553 · Cited by 45
Self-citationThe Effect of Dexamethasone on the Pharmacokinetics of Triazolam
Villikka, K., Kivistö, K. T., & Neuvonen, P. J. (1998) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1998.tb01457.x · Cited by 45
Berlin, I., Gasior, M., & Moolchan, E. T. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701243193 · Cited by 45
Otton, S. V., Brinn, R., & Gram, L. F. (1988) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06891-6 · Cited by 45
Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
Soars, M. G., Grime, K., & Riley, R. J. (2006) · Xenobiotica · doi:10.1080/00498250500446208 · Cited by 44
Lewis, D. F. V., Jacobs, M. N., Dickins, M., & Lake, B. G. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00135-x · Cited by 43
Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines
Korjamo, T., Honkakoski, P., Toppinen, M.-R., Niva, S., Reinisalo, M., Palmgrén, J. J., & Mönkkönen, J. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.06.004 · Cited by 43
Self-citationSchmider, J., Moltke, L. L., Shader, R. I., Harmatz, J. S., & Greenblatt, D. J. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101935 · Cited by 43
Poso, A., & Honkakoski, P. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706777935008 · Cited by 40
Self-citationMontelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., Niemi, M., & Neuvonen, P. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0136-9 · Cited by 40
Local Kinetics and Dynamics of Xenobiotics
Pelkonen, O., Kapitulnik, J., Gundert‐Remy, U., Boobis, A. R., & Stockis, A. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440802194931 · Cited by 40
Self-citationPreclinical Development Handbook
(2007) · Wiley eBooks · doi:10.1002/9780470249055 · Cited by 39
Chien, J. Y., Peter, R. M., Nolan, C. M., Wartell, C., Slattery, J. T., Nelson, S. D., Carithers, R. L., & Thummel, K. E. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90179-x · Cited by 39
Lim, P. L. K., Tan, W., Latchoumycandane, C., Mok, W. C., Khoo, Y. M., Lee, H. S., Sattabongkot, J., Beerheide, W., Lim, S. G., Tan, T. M. C., et al. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.05.003 · Cited by 38
Role of Human CYP2B6 in S-Mephobarbital N-Demethylation
Kobayashi, K., Abe, S., Nakajima, M., Shimada, N., Tani, M., Chiba, K., & Yamamoto, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14953-7 · Cited by 38
Allqvist, A., Miura, J., Bertilsson, L., & Mirghani, R. A. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0230-z · Cited by 37
Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor
van Giersbergen, P. L. M., Gnerre, C., Treiber, A., Dingemanse, J., & Meyer, U. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02075-7 · Cited by 37
Amet, Y., Berthou, F., Baird, S., Dréano, Y., Bail, J. P., & Menez, J. F. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02040-3 · Cited by 36
Insights from a Three-Dimensional Model into Ligand Binding to Constitutive Active Receptor
Xiao, L., Cui, X., Madison, V., White, R. E., & Cheng, K.-C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.9.951 · Cited by 36
Lecamwasam, D., Franklin, C. S., & Turner, P. (1975) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1975.tb01584.x · Cited by 36
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011965 · Cited by 35
Madan, A. (2002) · Medical Entomology and Zoology · Cited by 35
Becquemont, L., Bot, M. A. L., Richeb, C., Funck‐Brentano, C., Jaillon, P., & Beaune, P. H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00002 · Cited by 34
Molecular Determinants of Steroid Inhibition for the Mouse Constitutive Androstane Receptor
Jyrkkärinne, J., Mäkinen, J., Gynther, J., Savolainen, H., Poso, A., & Honkakoski, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030861t · Cited by 34
Self-citationCRYOPRESERVED HUMAN HEPATOCYTES AS ALTERNATIVE IN VITRO MODEL FOR CYTOCHROME P450 INDUCTION STUDIES
Garcia, M., Rager, J. D., Wang, Q., Strab, R., Hidalgo, I. J., Owen, A. J., & Li, J. (2003) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1543-706x(2003)039<0283:chhaai>2.0.co;2 · Cited by 34
Hartley, D. P., Dai, X., Yabut, J. A., Chu, X., Cheng, O., Zhang, T., He, Y. D., Roberts, C., Ulrich, R. G., Evers, R., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000220561.59972.7a · Cited by 33
Li, Y., Li, N.-Y., & Sellers, E. M. (1997) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190960 · Cited by 33
Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
Mihara, K., Svensson, U. S. H., Tybring, G., Hai, T. N., Bertilsson, L., & Ashton, M. (1999) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1999.tb00379.x · Cited by 33
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174*
Goldberg, M. R., Lo, M. W., Deutsch, P., Wilson, S. E., McWilliams, E. J., & McCrea, J. B. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80004-x · Cited by 33
Interaction of secobarbital with warfarin pseudoracemates
O’Reilly, R. A., Trager, W. F., Motley, C. H., & Howald, W. N. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.149 · Cited by 33
Kim, K., Park, P., Kim, K. R., & Park, J. Y. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02764.x · Cited by 32
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
LAINE, K., Palovaara, S., TAPANAINEN, P., & MANNINEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.103404001 · Cited by 32
Heterogeneous Nuclear Ribonucleoprotein A1 and Regulation of the Xenobiotic-Inducible Gene Cyp2a5
Raffalli‐Mathieu, F., Glisovic, T., Ben‐David, Y., & Lang, M. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.4.795 · Cited by 32
Wang, K., Mendy, A. J., Dai, G., Luo, H., He, L., & Wan, Y. Y. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj207 · Cited by 31
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo
Villikka, K., Varis, T., Backman, J. T., et al. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100340 · Cited by 30
Virtual Screening for Aryl Hydrocarbon Receptor Binding Prediction
Piparo, E. L., Koehler, K., Chana, A., & Benfenati, E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060526f · Cited by 28
Yamazaki, H., HIROKI, S., Urano, T., Inoue, K., & Shimada, T. (1996) · Xenobiotica · doi:10.3109/00498259609050259 · Cited by 28
Development of a Versatile Platform for Nuclear Receptor Screening Using AlphaScreen™
Rouleau, N., Turcotte, S., Mondou, M.-H., Roby, P., & Bossé, R. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103252605 · Cited by 28
Verapamil disposition‐effects of sulphinpyrazone and cimetidine.
Wing, L., Miners, J. O., & Lillywhite, K. J. (1985) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1985.tb02658.x · Cited by 27
Frank, C., Molnár, F., Heinäniemi, M., Lempiäinen, H., & Carlberg, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403946200 · Cited by 26
Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human.
Eriksson, U. G., Lundahl, J., Bäärnhielm, C., et al. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08966-4 · Cited by 25
Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation
Osabe, M., Sugatani, J., Takemura, A., Yamazaki, Y., Ikari, A., Kitamura, N., Negishi, M., & Miwa, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.140 · Cited by 24
Single-dose disulfiram does not inhibit CYP2A6 activity*
Kharasch, E. D., Hankins, D. C., Baxter, P. J., & Thummel, K. E. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90020-0 · Cited by 24
Endo, T., Ban, M., Hirata, K., Yamamoto, A., Hara, Y., & Momose, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013425 · Cited by 24
Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6
Higashi, E., Nakajima, M., Katoh, M., Tokudome, S., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014084 · Cited by 24
Biotransformation of felodipine in liver microsomes from rat, dog, and man.
Bäärnhielm, C., Bäckman, A., Hoffmann, K. J., & Weidolf, L. O. G. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08882-8 · Cited by 24
Fukuda, I., Nishiumi, S., Yabushita, Y., Mukai, R., Kodoi, R., Hashizume, K., Mizuno, M., Hatanaka, Y., & Ashida, H. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.02.003 · Cited by 22
Windshügel, B., Jyrkkärinne, J., Küblbeck, J., Poso, A., Honkakoski, P., & Sippl, W. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2006.05.002 · Cited by 22
Self-citationExtrahepatic drug metabolizing enzymes
Kapitulnik, J., & Strobel, H. W. (1999) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(1999)13:5<227::aid-jbt1>3.0.co;2-1 · Cited by 22
Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver
Emoto, C., Yamato, Y., Sato, Y., Ohshita, H., Katoh, M., Tateno, C., Yokoi, T., Yoshizato, K., & Iwasaki, K. (2008) · Xenobiotica · doi:10.1080/00498250701760159 · Cited by 22
Enantiomers of Warfarin and Phenobarbital
Orme, M. L., & Breckenridge, A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197612232952613 · Cited by 22
The Time to Move Cytochrome P450 Induction into Mainstream Pharmacology Is Long Overdue
Smith, D. A., Dickins, M., Fahmi, O. A., Iwasaki, K., Lee, C. G. L., Obach, R. S., Padbury, G. E., de Morais, S. M., Ripp, S. L., Stevens, J., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013284 · Cited by 21
Tornheim, K. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1377 · Cited by 18
Biphasic interaction of phenytoin with warfarin.
Levine, M., & Sheppard, I. (1984) · PubMed · Cited by 17
Lavrijsen, K., Houdt, J. V., Dyck, D. M. J. V., Hendrickx, J. J. J. M., Woestenborghs, R. J. H., Lauwers, W., Meuldermans, W., & Heykants, J. (1988) · Anesthesiology · doi:10.1097/00000542-198810000-00013 · Cited by 15
Hrycay, E. G., & Bandiera, S. M. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse048 · Cited by 9
Preferential inhibition of CYP1A enzymes in hepatic microsomes by mexiletine
Konishi, H., MORITA, K., Minouchi, T., & Yamaji, A. (1999) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190360 · Cited by 9
Sun, X., Li, F., Wang, Y., Li, Y., Su, Y. Y., Li, Y., Yan, H., & Xu, S. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh137 · Cited by 7
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
“It is mostly transcriptional regulation, and mainly resulting from epigenetic regulation, although non-transcriptional mechanisms, such as enzyme stabilization, stabilization of mRNA, or inhibition of protein degradation, have also been reported [94].”
BackgroundAlternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Self-citationEsteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Biotransformation of Xenobiotics
Timbrell, J. A., & Marrs, T. C. (2009) · General, Applied and Systems Toxicology · doi:10.1002/9780470744307.gat004 · Cited by 435
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Self-citation
Metadata
- Authors
- Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H.
- Venue
- Archives of Toxicology
- Published
- 2008-07-11
- Volume
- 82
- Issue
- 10
- Pages
- 667-715
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2034400329
- Cited by
- 569
- References
- 582
- FWCI
- 36.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.